Chantix — Class II drug recall D-0701-2021
Ongoing recall by Pfizer Inc., reported 2021-08-11, distributed nationwide. CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intak
| Recall number | D-0701-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2021-06-09 |
| Classified | 2021-07-30 |
| Reported by FDA | 2021-08-11 |
| Distributed | Nationwide (US) |
| Quantity | 69,639 |
| Reason classes | cgmp, specification failure |
| NDC | 00069-0468, 00069-0468-56, 00069-0469, 00069-0469-28, 00069-0469-56, 00069-0471, 00069-0471-03, 00069-0471-28 |
| Lot numbers | EA6080, EC9843 |
Product
Chantix (varenicline) tablets, 1 mg, 56 Tablets, Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc., NY, NY 10017, Made in Ireland. NDC 0069-0469-56
Reason for recall
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0701-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.